| 摘要 |
<p>A biomarker is provided to use reaction genes selected from a DNA microarray chip for monitoring and determining teratogenicity and side effects of valproic acid during treatment of epilepsy and manic depressive. A biomarker for screening and diagnosing teratogenicity of valproic acid includes a gene selected from the group consisting of Genebank NM_001465, Genebank NM_005953, Genebank NM_005931, Genebank NM_021626, Genebank NM_145058, Genebank NM_003311, Genebank AF316855, Genebank NM_006705, Genebank NM_022157, Genebank NM_001005360, Genebank NM_006290, Genebank NM_002305, Genebank BC051787, Genebank NM_001446, Genebank NM_001386, Genebank NM_015103, Genebank NM_002165, Genebank NM_002166, Genebank NM_002167, Genebank NM_152243, Genebank NM_012234, Genebank NM_002389, Genebank AB044807, Genebank NM_017512, Genebank NM_018269, Genebank NM_004403, Genebank AK094629, Genebank NM_005139, Genebank NM_199286, Genebank NM_024091, Genebank NM_005871, Genebank NM_018147, Genebank NM_006265, Genebank NM_020371, Genebank NM_004331, Genebank NM_000254, Genebank NM_205842, Genebank NM_006522, Genebank AA399656, Genebank NM_004010, and Genebank NM_016441. A DNA microarray chip for screening the valproic acid is characterized in that an oligonucleotide including a total or a portion of the biomarker gene sequence or a complimentary strand molecule thereof is integrated. A method for screening and diagnosing the teratogenicity of the valproic acid comprises the steps of: (a) treating human choriocarcinoma cells with a compound to be tested; (b) isolating RNA respectively from the test group cells treated with the compound to be tested and control group cells; (c) labelling the test group and the control group, respectively, with a fluorescent material different from each other with synthesizing the RNA of the test group and the control group into cDNA; (d) hybridizing each the cDNA(s) labelled with the fluorescent material into the DNA microarray chip; (e) analyzing the reacted DNA microarray chip; and (f) comparing the expression degree of the biomarker from the data analyzed by the step(e) with that of the control group.</p> |
